In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and
mortality, which makes anticoagulation an integral part of treatment. However …

Introduction. Analysis of the pathogenesis of coronavirus infection caused SARS-CoV-2
indicates a significant impact of hemorheological disorders on its course and outcomes. It is …

The current pathophysiological knowledge of COVID-19 patients includes inflammation and
micro-thrombus, so hospitalized patients receive low-molecular weight and unfractionated …

Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …

Background During SARS-CoV-2 pandemic, the anticoagulant management in patients with
atrial fibrillation (AF) was simplified to the use of low molecular weight heparin (LMWH) in …

Background: Coronavirus disease 2019 (COVID-19) is associated with elevated rates of
major and fatal thrombotic events, postulated to be the result of a hypercoagulable state …

Abstract Coronavirus disease 2019 (COVID-19) is associated with a high incidence of
venous and arterial thromboembolic events. The role of anticoagulation (AC) prior to …

The COVID-19 pandemic has caused millions of cases and deaths, resulting in a public
health emergency. It is well established that 1 of the complications of infections in critically ill …

To The Editors The novel 2019 coronavirus disease (COVID-19) creates a hypercoagulable
state in which thrombotic microangiopathy, and a local disseminated intravascular …

Thromboprophylaxis has become an essential part of coronavirus-induced disease 2019
(COVID-19) therapeutic modality. A debate is ongoing as to which specific anticoagulant …